ADMA Biologics (NASDAQ:ADMA) PT Raised to $10.00 at HC Wainwright

ADMA Biologics (NASDAQ:ADMA) had its price objective increased by HC Wainwright from $7.50 to $10.00 in a research note issued on Friday, Benzinga reports. The brokerage presently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s target price suggests a potential upside of 44.30% from the stock’s current price.

A number of other analysts have also weighed in on the stock. Cantor Fitzgerald upped their target price on shares of ADMA Biologics from $6.50 to $8.00 and gave the stock an “overweight” rating in a report on Thursday, February 29th. Mizuho increased their price objective on ADMA Biologics from $9.00 to $10.00 and gave the stock a “buy” rating in a research report on Friday, March 1st. One analyst has rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Buy” and an average target price of $9.00.

ADMA Biologics Price Performance

ADMA Biologics stock opened at $6.93 on Friday. The firm has a market capitalization of $1.58 billion, a P/E ratio of -53.31 and a beta of 0.43. ADMA Biologics has a one year low of $3.06 and a one year high of $6.97. The company has a debt-to-equity ratio of 1.04, a current ratio of 5.16 and a quick ratio of 1.69. The business has a fifty day moving average price of $6.33 and a 200-day moving average price of $5.09.

ADMA Biologics (NASDAQ:ADMA) last issued its quarterly earnings data on Wednesday, February 28th. The biotechnology company reported $0.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.02 by $0.02. The business had revenue of $73.90 million for the quarter, compared to analysts’ expectations of $73.50 million. ADMA Biologics had a positive return on equity of 0.49% and a negative net margin of 10.94%. As a group, equities research analysts forecast that ADMA Biologics will post 0.3 EPS for the current year.

Insider Activity

In related news, Director Steve Elms sold 183,008 shares of the business’s stock in a transaction that occurred on Friday, March 15th. The stock was sold at an average price of $6.01, for a total value of $1,099,878.08. Following the completion of the sale, the director now owns 2,577,387 shares in the company, valued at approximately $15,490,095.87. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In the last three months, insiders have sold 639,895 shares of company stock worth $3,927,169. 3.70% of the stock is currently owned by insiders.

Institutional Trading of ADMA Biologics

Several hedge funds have recently added to or reduced their stakes in ADMA. Simplicity Wealth LLC purchased a new position in shares of ADMA Biologics in the first quarter worth about $68,000. Cambridge Investment Research Advisors Inc. increased its stake in ADMA Biologics by 31.3% in the 3rd quarter. Cambridge Investment Research Advisors Inc. now owns 15,000 shares of the biotechnology company’s stock worth $54,000 after purchasing an additional 3,572 shares during the period. Sawgrass Asset Management LLC bought a new stake in ADMA Biologics in the third quarter valued at approximately $55,000. Viewpoint Capital Management LLC boosted its stake in shares of ADMA Biologics by 18.6% during the first quarter. Viewpoint Capital Management LLC now owns 15,416 shares of the biotechnology company’s stock valued at $102,000 after purchasing an additional 2,416 shares during the period. Finally, DekaBank Deutsche Girozentrale bought a new position in shares of ADMA Biologics in the third quarter worth approximately $58,000. 75.68% of the stock is owned by institutional investors.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.